Skip to main content
main-content

01.12.2015 | Research article | Ausgabe 1/2015 Open Access

BMC Endocrine Disorders 1/2015

An association between liraglutide treatment and reduction in excessive daytime sleepiness in obese subjects with type 2 diabetes

Zeitschrift:
BMC Endocrine Disorders > Ausgabe 1/2015
Autoren:
Fernando Gomez-Peralta, Cristina Abreu, Jose Carlos Castro, Elvira Alcarria, Margarita Cruz-Bravo, Maria Jesús Garcia-Llorente, Cristina Albornos, Concepción Moreno, María Cepeda, Francisca Almodóvar
Wichtige Hinweise

Competing interests

F. Gomez-Peralta has participated in the Advisory Panel for Sanofi-aventis and Novo Nordisk; he has also participated as Research Support for Sanofi-aventis, Novo Nordisk, Boehringer Ingelheim, and Lilly; and has received honoraria for speaking for Sanofi-aventis, Novo Nordisk, Boehringer Ingelheim, AstraZeneca, Bristol-Myers Squibb, and Lilly. C. Abreu has participated as Research Support for Sanofi-aventis, Novo Nordisk, Boehringer Ingelheim, and Lilly; and has received honoraria for speaking from Sanofi-aventis, Novo Nordisk, Boehringer Ingelheim Pharmaceuticals, AstraZeneca, and Bristol-Myers Squibb. J.C. Castro has participated as Research Support for Sanofi-aventis, Novo Nordisk, Boehringer Ingelheim, and Lilly. E. Alcarria has participated as Research Support for Sanofi-aventis, Novo Nordisk, Boehringer Ingelheim, and Lilly. M. Cruz-Bravo has participated as Research Support for Sanofi-aventis, Novo Nordisk, Boehringer Ingelheim, and Lilly. M.J. Llorente has participated as Research Support for Sanofi-aventis, Novo Nordisk, Boehringer Ingelheim, and Lilly. C. Albornos has participated as Research Support for Sanofi-aventis, Novo Nordisk, Boehringer Ingelheim, and Lilly. C. Moreno has participated as Research Support for Sanofi-aventis, Novo Nordisk, Boehringer Ingelheim, and Lilly. M. Cepeda: None. F. Almodóvar has participated as Research Support for Sanofi-aventis, Novo Nordisk; and has received honoraria for speaking for Novo Nordisk and Lilly.

Authors’ contributions

All authors read and approved the final manuscript; their individual contribution was as follows: FGP: conception and design of the study, acquisition, analysis and interpretation of data, drafting the article and revising it critically, approval of final article; CA: acquisition of data, analysis and interpretation of data, revising the article critically, approval of final article; JCC: acquisition of data, revising the article critically, approval of final article; EA: acquisition of data, revising the article critically, approval of final article; MC-B: acquisition of data, revising the article critically, approval of final article; MJG-LL: acquisition of data, revising the article critically, approval of final article; CA: acquisition of data, revising the article critically, approval of final article; CM: acquisition of data, revising the article critically, approval of final article; MC: acquisition of data, revising the article critically, approval of final article; FA: acquisition of data; revising the article critically, approval of final article.

Abstract

Background

The main purpose of the present study is to evaluate whether treatment with long-acting human glucagon-like peptide-1 liraglutide was associated with an improvement of excessive daytime sleepiness (EDS) in obese subjects with type-2 diabetes.

Methods

This single-centre retrospective study included 158 obese (body mass index [BMI] ≥ 30 kg/m2) adult subjects with type-2 diabetes who were initiated with liraglutide treatment at least 3 months before study inclusion. Data of the Epworth Sleepiness Scale (ESS), anthropometric parameters, glucose-control and metabolic parameters were collected at liraglutide initiation (baseline) and at months 1 and 3 after liraglutide initiation.

Results

Significant reductions in ESS score were achieved at months 1 (−1.3 ± 2.8, p < 0.001) and 3 (−1.5 ± 3.0, p < 0.001) after liraglutide introduction. After 3 months of treatment with liraglutide, significant changes in body weight (p < 0.001), BMI (p < 0.001), waist (p < 0.001) and neck circumferences (p < 0.005), HbA1c (p < 0.001), mean blood glucose (p < 0.001), fasting plasma glucose (p < 0.001), triglycerides (p < 0.01) and total cholesterol (p < 0.001) were achieved.

Conclusions

After 3 months of treatment with liraglutide a significant reduction in EDS was observed in obese subjects with type-2 diabetes. Besides this, significant changes in body weight and metabolic parameters of diabetes control were also accomplished. Further investigation is required to determine whether liraglutide could improve other abnormal sleep patterns and obstructive sleep apnoea.
Literatur
Über diesen Artikel

Weitere Artikel der Ausgabe 1/2015

BMC Endocrine Disorders 1/2015 Zur Ausgabe

Neu im Fachgebiet Innere Medizin

Meistgelesene Bücher aus der Inneren Medizin

2017 | Buch

Rheumatologie aus der Praxis

Entzündliche Gelenkerkrankungen – mit Fallbeispielen

Dieses Fachbuch macht mit den wichtigsten chronisch entzündlichen Gelenk- und Wirbelsäulenerkrankungen vertraut. Anhand von über 40 instruktiven Fallbeispielen werden anschaulich diagnostisches Vorgehen, therapeutisches Ansprechen und der Verlauf …

Herausgeber:
Rudolf Puchner

2016 | Buch

Ambulant erworbene Pneumonie

Was, wann, warum – Dieses Buch bietet differenzierte Diagnostik und Therapie der ambulant erworbenen Pneumonie zur sofortigen sicheren Anwendung. Entsprechend der neuesten Studien und Leitlinien aller wichtigen Fachgesellschaften.

Herausgeber:
Santiago Ewig

Mail Icon II Newsletter

Bestellen Sie unseren kostenlosen Newsletter Update Innere Medizin und bleiben Sie gut informiert – ganz bequem per eMail.

© Springer Medizin 

Bildnachweise